🍓🍓The global community will be able to use the cPass™ as unlike conventional test kits it does not require live biological materials or biosafety containment for testing.
🍓🍓This test would be instrumental in vaccine and therapeutic development as it is suitable for all antibody isotypes and can be used to determine antibodies in different animal species without any modification.
🍍🍍Singapore, 15 May 2020 – Duke-NUS Medical School (Duke-NUS), a research intensive graduate-entry medical school, GenScript Biotech Corporation (“GenScript”, Stock Code: 1548.HK), a leading global biotechnology company, and the Diagnostics Development Hub (DxD) at Singapore’s Agency for Science, Technology and Research (A*STAR), today announced an exclusive agreement to co-develop and manufacture a unique serological coronavirus (COVID-19) detection system known as the surrogate virus neutralisation test (sVNT) or cPass™. This test is the first in the world that allows rapid detection of neutralising antibodies (NAbs) – the specific antibodies present in the serum of COVID-19 patients that are responsible for clearing the viral infection, without the need of live biological materials and biocontainment facility.
🍍🍍See more: https://nus.edu/2zHWc25